Turning Point Therapeutics Inc (TPTX)


Stock Price Forecast

Aug. 17, 2022


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Turning Point Therapeutics Inc chart...

About the Company

Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company's lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib, which is being studied in a registrational Phase 2 study in adults and a Phase 1/2 study in pediatric patients, has shown antitumor activity and durable responses among kinase inhibitor treatment-naïve and pre-treated patients. The company's pipeline of drug candidates also includes TPX-0022, targeting MET, CSF1R and SRC, which is being studied in a Phase 1 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, targeting RET, which is being studied in a Phase 1/2 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in RET; and TPX-0131, a next-generation ALK inhibitor currently pending IND submission. Turning Point's next-generation kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to potentially overcome treatment resistance common with other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.

Exchange

NASDAQ

Website

tptherapeutics.com

$249M

Total Revenue

142

Employees

$4B

Market Capitalization

-13.49

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $TPTX News

With seeds from Turning Point, a new biotech blooms with $100M to take on small molecules

18d ago, source: FierceBiotech

The first signs of spring are beginning to emerge and so too are the shoots of the next biotech from drug designer J. Jean Cui, Ph.D. BlossomHill Therapeutics has raised $100 million in a series B ...

Turning Point Brands Inc.

1d ago, source: Wall Street Journal

No significant news for in the past two years. Key Stock Data P/E Ratio (TTM) The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...

Bihua Chen's Net Worth

1mon ago, source: Benzinga.com

This is based on reported shares across multiple companies, which include Corbus Pharmaceuticals Holdings, Inc., MoonLake Immunotherapeutics, Turning Point Therapeutics, Inc., Vigil Neuroscience ...

Turning Point Brands (NYSE: TPB)

5d ago, source: The Motley Fool

Turning Point Brands, Inc. engages in manufacturing, marketing, and distributing branded consumer products including alternative smoking accessories and consumables with active ingredients.

Omega Therapeutics: 2023 Could Well Be A Turning Point

10mon ago, source: Hosted on MSN

Among US-listed biotech stocks with promising prospects, investors should consider holding a position in Omega Therapeutics, Inc. as the company calls 2023 a pivotal year. Omega Therapeutics is a ...

Turning Point USA Founder Charlie Kirk Is Selling His Scottsdale Mansion for $6.5M

2d ago, source: SFGate

Charlie Kirk, founder of the conservative youth activist organization Turning Point USA, is turning away from his Scottsdale, ...

Turning Point Brands, Inc. (TPB) Q4 2023 Earnings Call Transcript

19d ago, source: Seeking Alpha

Ladies and gentlemen, good morning, and welcome to the Turning Point Brands' Fourth Quarter 2023 Earnings Conference Call. All participants will be in listen-only mode. All lines have been placed ...

Rapid Novor and MAbSilico partner for world's first AI-guided epitope mapping service for antibodies

10h ago, source: News Medical on MSN

Rapid Novor and MAbSilico partner to provide the world's first comprehensive AI-guided epitope mapping service. This service ...

drugs

11mon ago, source: Entrepreneur

Substance abuse and addiction have long posed challenges for employers and employees alike. However, the COVID-19 pandemic exacerbated these issues, leaving many companies struggling to support ...

Intellia Therapeutics Inc NTLA

3d ago, source: Morningstar

We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished ...

Cormorant Asset Management, LP's Net Worth

1mon ago, source: Benzinga.com

Who is Cormorant Asset Management, LP? Cormorant Asset Management, LP has an estimated net worth of $1.28 Billion. This is based on reported shares across multiple companies, which include Corbus ...

Turning Point Brands Inc (TPB)

1mon ago, source: Investing

Today, we move on to the opposite end of the spectrum,... Turning Point Brands, Inc., together with its subsidiaries, manufactures, markets, and distributes adult consumer products. It operates ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...